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APPLICATION OF THE NON-LINEAR BLINDER-OAXACA DECOMPOSITION TO
STUDY RACIAL/ETHNIC DISPARITIES IN ANTI-OBESITY MEDICATION USE
Mehta HB, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: The Blinder-Oaxaca (BO) decomposition helps to identify the causes
of disparity between two groups based on observed characteristics, and quantifies
the residual disparity due to unobserved heterogeneity. This study uses the non-
linear BO decomposition, an extension of the original BO decomposition, to iden-
tify and quantify the observed causes behind the racial/ethnic disparity in anti-
obesity medication use among US adults who met the medical criteria to receive
these medications. METHODS: The Medical Expenditure Panel Survey data, 2002-
2007, was used in this retrospective cross-sectional study. Themedical criteria was
defined as adults (age20 years) with bodymass index (BMI)30, or with BMI27
and comorbidities such as hypertension, cardiovascular diseases, diabetes or hy-
perlipidemia. The non-linear BO decomposition method was used to identify the
contribution of each observed socio-demographic and health characteristic in ex-
plaining the racial/ethnic disparity and to estimate the residual unexplained
disparity. RESULTS: A total of 395,319,750 adults met medical criteria from 2002-
2007; of which, 0.61% used anti-obesity medications. The proportion of medically
eligible Blacks using anti-obesitymedicationwas 33% lower thanWhites. The non-
linear BO decomposition method revealed that only marital status explained the
racial/ethnic disparity among the observed characteristics. Blacks were younger,
had a higher proportion of women in the sample, and had a higher BMI, and these
characteristics were the chief determinants of increased anti-obesity medication
use. Thus, the decomposition estimated that if the blacks had similar characteris-
tics as the whites the observed disparity in the sample would have been 58%
higher. CONCLUSIONS: The decomposition revealed interesting but disconcerting
findings. None of the differences in the observed socio-demographic and health
characteristics (except marital status) successfully explained the racial disparity.
Thus, further exploratory studies examining racial differences in individual beliefs,
behavioral patterns and provider prescription patterns are vital to understand
these disparities.
PSY55
NATIONAL TRENDS IN ANTI-OBESITY MEDICATION USE FROM 2002 TO 2007
Mehta HB, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: The US ranks first among all developed countries for obesity/over-
weight prevalence. Anti-obesity medications may help address this public health
problem, but national utilization data for anti-obesity medications is lacking. The
study objective was to examine trends in anti-obesity medication use among
adults who met medical criteria (MC) and understand the extent of use of such
medications among adultswho did notmeetMC.METHODS:A retrospective cross-
sectional study was performed using the Medical Expenditure Panel Survey data
from 2002-2007. The study comprised all non-pregnant adults (20 years of age;
N210,829,728). Meeting the MC for anti-obesity medication use for an individual
was defined as having Body Mass Index (BMI)  30 (clinically obese) or having BMI
 27 with comorbidities such as hypertension, cardiovascular disease, diabetes
and hyperlipidemia. Anti-obesity medications were identified from prescription
medicine files using national drug codes and drug names. Proportions of anti-
obesity medication users among adults whomet MC were calculated for each year
and logistic regression was performed to test utilization trends. Descriptive anal-
ysis was conducted to assess proportion of adults using anti-obesity medications
who did not meet MC. RESULTS: Of the adults who met MC (N65,886,625), 0.52%
were taking anti-obesity medications. Analysis of multiyear data showed no sta-
tistically significant trend (p-value  0.25) in anti-obesity medication use among
adultswhometMC from2002 to 2007. Of all US adultswhowere taking anti-obesity
medications (N542,297), 31.98% did not meet MC for use. CONCLUSIONS: Less
than one percent of eligible adults used anti-obesity drugs in each year and anti-
obesity medication use did not change from 2002 to 2007. Almost one third of
anti-obesity medication users did not meet MC. Given the associated side-effects
for these medications, further research is needed to understand the use of anti-
obesity medications among adults who do not meet MC.
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CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION
DRUG MONITORING PROGRAMS
Talbert J, Perin N, Blumenschein K, Freeman PR
University of Kentucky, Lexington, KY, USA
OBJECTIVES:Over 40 states have prescription drugmonitoring programs (PDMP) to
monitor the utilization of controlled substances (CS) with the goal of reducing drug
abuse and diversion. Little is known about how PDMPs are actually used by health
care professionals. The purpose of this paper is to review how prescribers utilize
PDMPs and to assess the impact of a PDMP onCS prescribing.METHODS:The paper
uses data from the Kentucky All Schedule Prescription Electronic Reporting Pro-
gram (KASPER) from 2002-2009. We review CS prescribing and KASPER utilization
using descriptive statistics, visualization, and t-test, controlling for characteristics
of KASPER users, the number of KASPER requests for each user type, and geo-
graphic distribution. Statistical analysis is conducted in STATA v11.0. RESULTS: CS
prescriptions issued by Kentucky prescribers increased from 8.4 million in 2002 to
over 11million in 2009. During this period, KASPER system requests increased from
100,000 in 2002 to more than 530,000 in 2009. Yet, most CS prescribers (64%) do not
have KASPER accounts. Comparing KASPER users across geographic regions, rural
areas have a higher (49%) rate of KASPER use than urban areas (32%, p.05). For CS
prescribing, the typical KASPER account holder issued 1,665 prescriptions a year in
2009, compared to 250 prescriptions issued by non-account holders. The top CS
prescriber in 2009 issued over 41,000 prescriptions, an increase of 60% from the top
prescriber in 2005. Finally, CS prescribing has become skewed, with 10% of pre-
scribers issuing 95% of all CS prescriptions. CONCLUSIONS: Since 2004, CS pre-
scribing in Kentucky has increased by 40% and KASPER system requests have in-
creased by 400%. The most interesting finding is that the majority of growth in CS
prescribing is froma relatively small number of prescribers.Whether this finding is
a direct result of the PDMP is a question for further research.
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DOES CLINICAL DIAGNOSIS OF OBESITY INCREASE THE LIKELIHOOD OF
RECEIVING OBESITY RELATED COUNSELING? A 2005-2008 NAMCS-NHAMCS
ANALYSIS
Kadakia A, Mehta H, Rajan SS, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: Studies have shown that despite the national guidelines recommend-
ing counseling for obese patients, counseling rates during outpatient visits remain
low. We determined the trends for obesity counseling (diet, exercise and weight
reduction) from year 2005 to 2008 and the association between being clinically
diagnosed with obesity and being counseled, for obese adults during their outpa-
tient visits. We also determined if clinical diagnosis of obesity varied with obesity
class which is classified by BMI. METHODS: We used the data from 2005 to 2008
National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambu-
latory Medical Care Survey (NHAMCS). The study included all adults having Body
Mass Index (BMI)  30. The outcome of interest was whether the patient received
obesity counseling or not. RESULTS: 478 million patients had BMI  30 of which
only 6%were clinically diagnosedwith obesity, and 31% received counseling. There
was no statistically significant change in counseling for obese adults from the year
2005 to 2008. Patients clinically diagnosed with obesity had 7.7 times (95% CI: 5.3-
11.1) greater odds of receiving counseling as compared to undiagnosed obese pa-
tients after controlling for sociodemographic and clinical factors. Moreover, class II
(35.5 BMI39.9) and class III (BMI40) obese patients had 1.8 (95%CI: 1.4-2.4) and
4.5 (95%CI: 3.4-6.0) times greater odds of being diagnosedwith obesity as compared
to class I (30 BMI  34.4) obese patients. CONCLUSIONS: Being clinically diag-
nosed with obesity is an indicator of access to care, and the patient’s initiatives to
seek obesity-related care. Our finding of low rates of counseling for diet, exercise or
weight reduction during visits by obese patients indicates that obesity is commonly
under-diagnosed. Interventions should focus on patient awareness strategies to
increase the rate of clinical diagnosis and hence counseling.
PSY58
DISPARITY IN OBESITY MANAGEMENT: UNDER-TREATMENT AMONG ELDERLY
POPULATION
Shah AJ, Patel JG, Rajan SS, Abughosh S, Masilamani S
University of Houston, Houston, TX, USA
OBJECTIVES: Obesity is a major cause of morbidity and mortality and a rising
epidemic worldwide. Despite guideline recommendations, many obese patients
fail to receive adequate medical care. The objectives of the study were to examine
predictors of obesity treatment and assess differences in receiving treatment be-
tween various age groups. METHODS: The study used data from 2006-2008 Na-
tional Ambulatory Medical Care Survey and National Hospital Ambulatory Medical
Care Survey. Adults with age  20 years were included and obesity was defined as
having a BMI 30. Obesity treatment was defined as the receipt ofmedication (like
Sibutramine, Orlistat, etc.) and/or obesity counseling in terms of weight reduction,
exercise, or diet counseling. Splines were constructed to assess changes in obesity
treatment with age. Descriptive statistics andmultivariate logistic regression were
used to determine predictors of receiving obesity treatment. RESULTS: Out of 3.1
billion visits, 29.2% (95%CI:28.1–30.3%) were obese. Among those, 31.4% (95%CI:
28.2–34.6%) between ages 20-39; 32.5% (95%CI:29.6–35.4%) between ages 40-64 and
25.4% (95%CI:22.2–28.7%) above 64 years received treatment. Inmultivariatemodel,
a unit increase in age increased the likelihood to receive treatment by 1.8% (95%CI:
0.1–3.6%)within the age group 20-39 years; decreased the likelihood by 1.4% (95%CI:
2.3–0.4%)within 40-64 years; and decreased the likelihood by 3.4% (95%CI:5.0–1.7%)
above 64 years. Primary care physicians (OR–1.66, 95%CI:1.38-1.99), were approxi-
mately 70% more likely to provide treatment compared to specialists. Individuals
with comorbidities were more likely to receive treatment (OR-1.37, 95% CI:1.17-
1.60). A significant difference across geographical region was also observed.
CONCLUSIONS: Study suggests differences in obesity management across age
groups. Older adults were less likely to receive obesity treatment. Further research
is needed to ensure that quality care is provided across all age groups.
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IMPACT OF OBESITY ON AGE-SPECIFIC PREVALENCE OF CHRONIC DISEASES IN
THE UNITED STATES
Patel JG, Shah A, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: To examine prevalence of chronic comorbid diseases among obese
adults in the United States METHODS: Medical Expenditure Panel Survey Data
from2005 – 2007was used for the analysis. Adultswith age 20 years and BMI 30,
were defined obese. Unadjusted age-specific prevalence of hypertension, diabetes,
dyslipidemia, CHD, osteoarthritis and asthma were obtained among obese, non-
obese and entire population using descriptive analysis. Adjusted prevalence esti-
mates were obtained using regression analysis after controlling for socio-demo-
graphic factors. Age-specific prevalence ratios (relative risk) were obtained by
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taking ratios of predicted prevalence rates for obese versus non-obese individuals.
Bootstrapped 95% confidence intervals were generated for prevalence ratios.
RESULTS: Among obese adults the unadjusted prevalence of hypertension was
(34.40%), followed by dyslipidemia (21.87%), diabetes (16.34%) and asthma (6.92%).
Adjusted prevalence of chronic diseases was always higher among obese as com-
pared to non-obese and the entire population. The prevalence ratio for diabetes
was 3.06 (95% C.I: 2.82 – 3.30) at the age of 20 and was 2.20 (95% C.I: 2.09 – 2.31) at 70
years. At any age, obesity increases the likelihood of these conditions by at least
50% as compared to non-obese individuals. CONCLUSIONS: Prevalence ratios in-
dicate that obesity has highest impact on prevalence of diabetes; followed by hy-
pertension, osteoarthritis, dyslipidemia. Study findings suggest that obesity is not
only a disease, but may also be a cause for other chronic disorders. There is a need
to develop effective interventions to combat obesity and thus minimize its impact
on other diseases in the United States.
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ECONOMIC CONSEQUENCES OF UNDER-UTILIZATION WITH TUMOR NECROSIS
FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS
Carter C1, Gunnarsson C2, Rizzo J3, Bolge S1, Ingham M1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc.,
Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA
OBJECTIVES: Adherence to Food and Drug Administration recommended admin-
istration with adalimumab, etanercept, or infliximab may be variable. Suboptimal
adherence patterns may contribute to health care cost increases. This study esti-
mated incremental health care costs of tumor necrosis factor inhibitor (anti-TNF)
under-utilization from amanaged care perspective.METHODS:Medical/pharmacy
claims from the LifeLink™ Health Plan database were used. Inclusion criteria in-
cluded: index anti-TNF started January 1, 2004-December 31, 2007, age18 years, 2
pre-index rheumatoid arthritis diagnosis codes (ICD-9 code 714.xx), 365 days of
index drug, continuous enrollment 6/12months pre-/post-index. Exclusion criteria
included: switching biologics post-index and selected inflammatory conditions.
Under-utilization events were defined as prescriptions/infusions with 10% less
than recommended dosing for adalimumab (40 mg every other week/weekly with/
withoutmethotrexate), etanercept (50mgweekly), or infliximab (3mg/kg dose and
maintenance infusion interval  56 days). Incremental increases in health care
costs for patients with under-utilization, compared to receiving recommended
dosing, were estimated using cost regression models controlling for refill/infusion
intervals. Models were estimated for a 12-month time horizon and until index drug
discontinuation or loss of enrollment. RESULTS:A total of 4,586 RA patients receiv-
ing adalimumab (N1,255; 27,540 prescriptions), etanercept (N2,242; 48,517 pre-
scriptions), or infliximab (N1,089; 19,656 infusions) were included. Mean lengths
of time (days) patients received adalimumab (856), etanercept (881), and infliximab
(903) were comparable. Proportion of under-utilization events were 16%, 39%, and
2% for adalimumab, etanercept, and infliximab, respectively. Adalimumab or et-
anercept under-utilization was significantly associated with incremental in-
creased health care costs ($2,352 and $879; p0.01) for 12 months and through end
of data ($4,677 and $3,806; p0.01). Infliximabunder-utilizationwas infrequent and
not associated with increased health care costs. CONCLUSIONS: In this analysis,
adalimumab or etanercept under-utilization was associated with increased total
healthcare costs; however, infliximab under-utilization did not have a similar re-
sult. Additional research assessing clinical consequences of under-utilization is
warranted.
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CHARACTERISTICS OF GOLIMUMAB UTILIZATION AND COSTS IN A SPECIALTY
PHARMACY PROVIDER (SPP) SETTING
Ellis L1, Tandon N1, Mody S1, Doshi D1, Baek C2, Gunnarsson C3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Diplomat Pharmacy, Wartz Creek,
MI, USA, 3S2 Statistical Solutions, Inc., Cincinnati, OH, USA
OBJECTIVES:Golimumab is a 50milligram (mg), oncemonthly, injected anti-tumor
necrosis factor alpha therapy for treatment of rheumatoid arthritis, ankylosing
spondylitis and psoriatic arthritis. This study calculated expected costs of annual
golimumab therapy based upon observed dosing patterns within a SPP population
during the first 16 months of golimumab availability. METHODS: Pharmacy and
corresponding eNAVIGATORTM patient care management data were collected by
Diplomat Specialty Pharmacy, Flint, MI for adult patients with a golimumab pre-
scription between 4/24/2009 and 8/24/2010. Datawere analyzed statistically and are
reported as n, %, meanstandard deviation (SD) and median. Costs were modeled
in US dollars using the wholesale acquisition cost (WAC; effective 6/9/2010) of
$1,731.48 per 50 mg. RESULTS: The study included 89 patients. The majority were
female (65%); age 45 years (69%); and reported prior biologic use (56%). A 50 mg
golimumab dose was dispensed in 100% of patients and 100% of all doses. The
mean (SD) interval between golimumab doses was 32.0 14.1 days and the me-
dian was 28 days. The mean golimumab dosing interval in patients reporting bio-
logic use prior to golimumab initiation was 32.915.9 days (meanSD) and was
similar to the mean dosing interval observed in patients reporting no biologic use
prior to golimumab initiation (meanSD: 31.112.1 days; p0.15; NS). Based upon
modeling of these early observations, the average golimumab patient will utilize
approximately 11.4 doses of golimumab annually at a cost of $19,739 (WAC).
CONCLUSIONS: In this SPP population, all patients received 50 mg of golimumab.
The mean and median times between distribution of golimumab doses were 32
days and 28 days, respectively. Based upon the dosing and distribution patterns
observed, the estimated average annual per patient cost of golimumab would be
$19,739. Golimumab utilization may be similar for patients regardless of prior use
of biologic therapies.
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PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC
THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS
Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: To identify perceived benefits and disadvantages of intravenous in-
fusion (IV) biologic therapy among patients with immunology conditions currently
treated with IV biologic medication. METHODS: Semi-structured telephone inter-
views were conducted with patients self-reporting a diagnosis of ankylosing spon-
dylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, or ulcer-
ative colitis and currently receiving IV biologic therapy. Study protocol and
questionnaire were approved by an independent institutional review board. Pa-
tients rated satisfactionwith current IVmedication on a 7-point Likert scale, where
1 not at all satisfied and 7very satisfied. Patients also discussed benefits and
disadvantages of IV biologic therapy and reasons for IV preference. RESULTS: 405
interviews were conducted. Mean satisfaction was 6.1; 77% rated satisfaction as 6
or 7. The most frequently described benefits of IV therapy related to healthcare
professional monitoring and oversight at time of infusion. More than half of pa-
tients also experience a social benefit of IV administration, including talking to
other patients about experiences (56%) and tying-in other activities with infusion
facility visits (55%). Most commonly described disadvantages of infusion were du-
ration of infusion (41%) and scheduling issues (23%). Of current IV users,most (82%,
n332) prefer an IV medication to a subcutaneous injection. The most common
reasons for IV preference were: not wanting to self-inject (43%), less frequent dos-
ing (34%), and preference for healthcare professional administration (24%). Satis-
faction with medication and perceived benefits varied somewhat by demograph-
ics, immunologic condition, and factors related to treatment. CONCLUSIONS:
Current IV biologic users are highly satisfied with their medications. Patients per-
ceive the additional opportunity for healthcare provider interaction at infusion
facilities as a benefit of thismode of administration. These results support the need
for continued patient access to IV therapeutic options and shared decision-making
between patients and physicians when selecting biologic treatment.
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LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS
ACROSS 30 INFUSIONS
Carter C1, Haas S2, Gunnarsson C2, Rizzo J3, Ingham M1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc.,
Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA
OBJECTIVES: Infliximab (IFX) is an infusible anti-tumor necrosis factor (anti-TNF)
drug used in the treatment of rheumatoid arthritis (RA), with Food and Drug Ad-
ministration (FDA) recommended administrations of 3 mg/kg at weeks 0, 2, 6, and
every 8 weeks thereafter. Dose increases up to 10 mg/kg or decreases in infusion
intervals to every 4 weeks may be appropriate based on individual response. Lim-
ited data are available presenting weight-based dosing, total quantity adminis-
tered, and infusion intervals simultaneously over the course of 30 infusions. The
objective of this studywas to calculateweight-based dosing, total quantity infused,
and infusion intervals for RA patients receiving IFX. METHODS: An event-level
analysis was conducted using medical/pharmacy claims from the IMS LifeLink™
Health Plan database. Inclusion criteria included: IFX initiation January 1, 2004-
December 31, 2007 (i.e., index date); patient age18 years old; 2 RA diagnosis codes
(ICD-9 714.xx); and 365 days of IFX persistence (i.e., number of days between first
and last IFX treatment). Patients were excluded if they had: psoriatic arthritis
(ICD-9 696.0), psoriasis (ICD-9 696.1), ulcerative colitis (ICD-9 556.xx), Crohn’s dis-
ease (ICD-9 555.xx), or ankylosing spondylitis (ICD-9 720.0); evidence of any anti-
TNF during the 6 months prior to index date; or evidence of taking abatacept or
rituximab while on IFX. RESULTS: There were 19,656 IFX infusion events (N1,089)
identified. Themedian weight-based doses spanned 3.0-4.2 mg/kg. Overall median
quantity infused at each infusion spanned 330-477 mg. Median infusion intervals
spanned 50-56 days for infusions 4-20. The median infusion intervals spanned
44-50 days for infusions 21-30. CONCLUSIONS: The observed IFX administration
schedule was consistent with FDA-approved prescribing of weight-based dosing
and infusion intervals over the course of 30 infusions. These data contribute to the
published literature by describing a consistent real-world administration schedule
over a longer period of time compared to other published studies.
PSY64
GE CENTRICITY® ELECTRONIC MEDICAL RECORDS STUDY: COMORBIDITIES
AND BIOLOGIC EXPERIENCE AMONG PATIENTS RECEIVING GOLIMUMAB
Tandon N1, Carter C1, Haas S2, Gunnarsson C2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc.,
Cincinnati, OH, USA
OBJECTIVES: Golimumab is the first and only monthly subcutaneous fully human
anti-TNF approved in the treatment of rheumatoid arthritis (RA), psoriatic arthritis
(PsA), and ankylosing spondylitis (AS). This study evaluated co morbidities and
pre-index biologic use among patients who received golimumab in the GE Centric-
ity® electronic medical records (EMR) database.METHODS: Longitudinal EMR data
were collected from outpatient practices in the United States. It contains clinical
information on over 15 million patients through September 2010. Patients were
selected based on the following criteria: 1ICD-9 diagnosis of RA, PsA, or AS; 18
years of age at the time of the first diagnosis; data 6-months prior and 3-months
after a prescription record of the first biologic, and at least one prescription record
for golimumab. Biologic experience was defined as use of a biologic within 6
months prior to the first golimumab record. RESULTS: A total of 153 [118 (RA); 20
(PsA); 15 (AS)] patients receiving golimumab were identified as meeting all the
inclusion criteria. The mean age was 49 years and 75% were female; 101 (66%)
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